Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity CLARITY PHARMACEUTICALS LTD ABN/ARBN Financial year ended: 36143005341 30 JUNE 2026 Our corporate...
Appendix 4G
Filed with ASX ·
On 6ix: 6ix.com/news/appendix-4g-102
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Annual Report to shareholders
- Ceasing to be a substantial holder
- Becoming a substantial holder
- Date of Annual General Meeting 25 November 2026
- Preliminary Final Report
Later from Clarity Pharmaceuticals
- Corporate governance statement
- SECuRE update
- SAR-bisPSMA Presentation - Drug & Device Conference
- Notice of Annual General Meeting/Proxy Form
- Ph III CLARIFY trial target number of participants achieved
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals